T regulatory cells in cancer: Recent advances and therapeutic potential

Eyad Elkord, Erik M. Alcantar-Orozco, Simon J. Dovedi, Dat Q. Tran, Robert E. Hawkins, David E. Gilham

Research output: Contribution to journalReview article

72 Citations (Scopus)

Abstract

Importance of the field: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. Areas covered in this review: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. What the reader will gain: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. Take home message: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.

Original languageEnglish
Pages (from-to)1573-1586
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 2010
Externally publishedYes

Fingerprint

Regulatory T-Lymphocytes
Tumors
Neoplasms
Therapeutics
Active Immunity
Tumor Microenvironment
Tumor Biomarkers
Immunotherapy
Immunity
Survival

Keywords

  • Cancer
  • Immunotherapy
  • T regulatory cells
  • Therapeutic strategies
  • Treg markers

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Elkord, E., Alcantar-Orozco, E. M., Dovedi, S. J., Tran, D. Q., Hawkins, R. E., & Gilham, D. E. (2010). T regulatory cells in cancer: Recent advances and therapeutic potential. Expert Opinion on Biological Therapy, 10(11), 1573-1586. https://doi.org/10.1517/14712598.2010.529126

T regulatory cells in cancer : Recent advances and therapeutic potential. / Elkord, Eyad; Alcantar-Orozco, Erik M.; Dovedi, Simon J.; Tran, Dat Q.; Hawkins, Robert E.; Gilham, David E.

In: Expert Opinion on Biological Therapy, Vol. 10, No. 11, 11.2010, p. 1573-1586.

Research output: Contribution to journalReview article

Elkord, E, Alcantar-Orozco, EM, Dovedi, SJ, Tran, DQ, Hawkins, RE & Gilham, DE 2010, 'T regulatory cells in cancer: Recent advances and therapeutic potential', Expert Opinion on Biological Therapy, vol. 10, no. 11, pp. 1573-1586. https://doi.org/10.1517/14712598.2010.529126
Elkord, Eyad ; Alcantar-Orozco, Erik M. ; Dovedi, Simon J. ; Tran, Dat Q. ; Hawkins, Robert E. ; Gilham, David E. / T regulatory cells in cancer : Recent advances and therapeutic potential. In: Expert Opinion on Biological Therapy. 2010 ; Vol. 10, No. 11. pp. 1573-1586.
@article{024f98b8a73e4ba5b289d582885f1f62,
title = "T regulatory cells in cancer: Recent advances and therapeutic potential",
abstract = "Importance of the field: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. Areas covered in this review: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. What the reader will gain: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. Take home message: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.",
keywords = "Cancer, Immunotherapy, T regulatory cells, Therapeutic strategies, Treg markers",
author = "Eyad Elkord and Alcantar-Orozco, {Erik M.} and Dovedi, {Simon J.} and Tran, {Dat Q.} and Hawkins, {Robert E.} and Gilham, {David E.}",
year = "2010",
month = "11",
doi = "10.1517/14712598.2010.529126",
language = "English",
volume = "10",
pages = "1573--1586",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - T regulatory cells in cancer

T2 - Recent advances and therapeutic potential

AU - Elkord, Eyad

AU - Alcantar-Orozco, Erik M.

AU - Dovedi, Simon J.

AU - Tran, Dat Q.

AU - Hawkins, Robert E.

AU - Gilham, David E.

PY - 2010/11

Y1 - 2010/11

N2 - Importance of the field: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. Areas covered in this review: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. What the reader will gain: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. Take home message: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.

AB - Importance of the field: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies. Areas covered in this review: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy. What the reader will gain: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity. Take home message: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.

KW - Cancer

KW - Immunotherapy

KW - T regulatory cells

KW - Therapeutic strategies

KW - Treg markers

UR - http://www.scopus.com/inward/record.url?scp=77958499613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958499613&partnerID=8YFLogxK

U2 - 10.1517/14712598.2010.529126

DO - 10.1517/14712598.2010.529126

M3 - Review article

C2 - 20955112

AN - SCOPUS:77958499613

VL - 10

SP - 1573

EP - 1586

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 11

ER -